"English People Don't Really Want to Feel that Much." The Curious Tale of Robert Smith's Least Favourite Cure Album, Despite Him Telling the World "Anyone Who Doesn't Like This Just Doesn't Like the Cure"

Why It Matters

The album illustrates how legacy acts balance commercial expectations with artistic control, and how producer‑artist clashes can shape a record’s legacy. It signals that even successful releases may be internally contested, influencing future collaborations in the rock genre.

Key Takeaways

• The Cure signed a three‑album deal with ARTISTdirect’s I AM label.
• Producer Ross Robinson pushed the band to record one song per day.
• Album *The Cure* reached #7 US Billboard, #8 UK Albums Chart.
• Smith demoed 37 tracks, narrowed to 20 for recording.
• Despite success, Smith calls the album his least favourite.

Pulse Analysis

When The Cure entered the studio in late 2003, they were at a crossroads. Robert Smith, fresh off the self‑imposed finale of *Bloodflowers*, had just inked a three‑album contract with ARTISTdirect’s I AM label, a move that promised renewed commercial momentum. The partnership with Ross Robinson—renowned for his work with Korn and Slipknot—brought an unexpected metal‑infused intensity to a band traditionally anchored in gothic pop. Robinson’s insistence on recording a single track per day and demanding detailed emotional briefings from Smith forced the group into a high‑pressure environment that both sharpened performances and heightened tensions.

The resulting record, *The Cure*, blended the band’s signature melancholy with a raw, almost confrontational edge. Critics praised the album’s cohesive mood and noted its polished yet gritty production, while fans responded positively, propelling it to #7 on the U.S. Billboard 200 and #8 in the U.K. The commercial success demonstrated that legacy acts could still command chart relevance when paired with a producer who pushes them beyond comfort zones. However, the creative friction left a lasting imprint on the band’s internal dynamics, as Smith later admitted the process felt “outrageous” and emotionally taxing.

In hindsight, Smith’s 2024 confession that *The Cure* is his least‑favourite album adds a nuanced layer to its legacy. It underscores a broader industry lesson: chart performance does not always equate to artistic satisfaction. For established artists, the balance between producer influence, fan expectations, and personal vision remains delicate. The album’s story serves as a case study for musicians navigating new collaborations while preserving the essence that originally defined their sound.